| Schedule of Segment Loss |
The following table sets forth the Company’s segment loss disclosure for the three and six months ended June 30, 2026 and 2025 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Three Months Ended
June 30, |
|
|
Six Months Ended
June 30, |
|
| |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
| R&D – Compensation and benefits (excludes stock-based compensation) |
|
$ |
2,495 |
|
|
$ |
3,217 |
|
|
$ |
4,625 |
|
|
$ |
6,512 |
|
| R&D – Clinical trial costs |
|
|
1,331 |
|
|
|
2,448 |
|
|
|
3,943 |
|
|
|
5,298 |
|
| R&D – Outsourced services & Consulting |
|
|
2,200 |
|
|
|
3,132 |
|
|
|
4,409 |
|
|
|
5,514 |
|
| R&D – Lab and pharmacology supplies |
|
|
67 |
|
|
|
256 |
|
|
|
210 |
|
|
|
546 |
|
| R&D – Other costs (1) |
|
|
629 |
|
|
|
440 |
|
|
|
1,009 |
|
|
|
1,036 |
|
| G&A – Compensation and benefits (excludes stock-based compensation) |
|
|
1,893 |
|
|
|
1,528 |
|
|
|
3,276 |
|
|
|
3,102 |
|
| G&A – Professional service fees |
|
|
2,266 |
|
|
|
810 |
|
|
|
3,047 |
|
|
|
1,807 |
|
| G&A – Insurance |
|
|
136 |
|
|
|
202 |
|
|
|
335 |
|
|
|
420 |
|
| G&A – Other costs (2) |
|
|
542 |
|
|
|
618 |
|
|
|
1,003 |
|
|
|
1,344 |
|
| Facilities related |
|
|
6,720 |
|
|
|
2,400 |
|
|
|
9,243 |
|
|
|
4,699 |
|
| Stock-based compensation and depreciation |
|
|
4,480 |
|
|
|
2,010 |
|
|
|
6,134 |
|
|
|
4,124 |
|
| Impairment of property and equipment |
|
|
1,625 |
|
|
|
— |
|
|
|
1,625 |
|
|
|
— |
|
| Total operating expense |
|
|
24,384 |
|
|
|
17,061 |
|
|
|
38,859 |
|
|
|
34,402 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss from operations |
|
|
(24,384 |
) |
|
|
(17,061 |
) |
|
|
(38,859 |
) |
|
|
(34,402 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Interest and other income, net |
|
|
691 |
|
|
|
1,386 |
|
|
|
1,611 |
|
|
|
2,969 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Segment net loss |
|
$ |
(23,693 |
) |
|
$ |
(15,675 |
) |
|
$ |
(37,248 |
) |
|
$ |
(31,433 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (1) |
Includes expenses such as software licenses, database subscriptions, lab service contracts, travel, and other costs. |
| (2) |
Includes expenses such as travel, investor relations services, software licenses, employee training and development, and other costs. |
|
The following table sets forth the Company’s segment loss disclosure for the years ended December 31, 2025 and 2024 (in thousands):
|
|
|
|
|
|
|
|
|
| |
|
Year Ended December 31, |
|
| |
|
2025 |
|
|
2024 |
|
| R&D – Compensation and benefits (excludes stock-based compensation) |
|
$ |
10,601 |
|
|
$ |
13,758 |
|
| R&D – Clinical trial costs |
|
|
9,850 |
|
|
|
11,507 |
|
| R&D – Outsourced services & Consulting |
|
|
11,826 |
|
|
|
19,022 |
|
| R&D – Lab and pharmacology supplies |
|
|
754 |
|
|
|
2,295 |
|
| R&D – Other costs (1) |
|
|
1,879 |
|
|
|
1,818 |
|
| G&A – Compensation and benefits (excludes stock-based compensation) |
|
|
5,744 |
|
|
|
6,438 |
|
| G&A – Professional service fees |
|
|
2,669 |
|
|
|
2,866 |
|
| G&A – Insurance |
|
|
821 |
|
|
|
678 |
|
| G&A – Other costs (2) |
|
|
2,413 |
|
|
|
2,333 |
|
| Facilities related |
|
|
9,619 |
|
|
|
3,951 |
|
| Stock-based compensation and depreciation |
|
|
7,376 |
|
|
|
8,601 |
|
|
|
|
|
|
|
|
|
|
| Total operating expense |
|
|
63,552 |
|
|
|
73,267 |
|
|
|
|
|
|
|
|
|
|
| Loss from operations |
|
|
(63,552 |
) |
|
|
(73,267 |
) |
| Interest and other income, net |
|
|
5,355 |
|
|
|
7,904 |
|
|
|
|
|
|
|
|
|
|
| Segment net loss |
|
$ |
(58,197 |
) |
|
$ |
(65,363 |
) |
|
|
|
|
|
|
|
|
|
| (1) |
Includes expenses such as software licenses, database subscriptions, lab service contracts, travel, and other costs. |
| (2) |
Includes expenses such as travel, investor relations services, software licenses, employee training and development, and other costs. |
|